BONGROS - HA Bone Chip : Optimum Porosity, Excellent Osteoconduction

Bongros - HA is identical to human bone's mineral in terms of physical and chemical Hydroxyapatite. It is the 1st Korean-made synthetic bone used to replace defected bone. It gradually unite to bone tissue and provides effective space in order to make new bone's ingrowths and maintain space until new bone tissue's ingrowths is completed.

Bongros- HA is indicated for spinal fusion, fracture repair, autograft extender, dental implants, and harvested site filler.

Key Features:

• 300 micrometers average pore size- ensures total bone and blood vessel penetration
• 70-80% porosity - provides optimum effective space from bone formation
• 3-dimensional interconnected pore structure- guarantees solid and fast bone formation
• Made from biocompatible and fully resorbable Hydroxyapatite Ceramic - eliminates risk of rejection and maintains effective space until new bone tissue ingrowths is completed
• Excellent Safety Profile - 100% safe from immune or inflammation reaction and cross infection.

Made available in the following sizes:
HAGE 1 10cc (Ortho)
HAGE 2 20cc (Ortho)
HAGE 3 30cc (Ortho)

HAGE 1 0.25cc (Dental)
HAGE 2 0.50cc (Dental)
HAGE 3 1.0 cc (Dental)

CURAVAC - Gold Standard in Wound Healing

PRODUCT DESCRIPTION

CuraVAC / Curasys system is a new and advanced wound treatment technology using negative pressure or vacuum assisted wound dressing. The system is composed of the consumable dressing (CuraVAC) and the reusable battery operated vacuum pump (Curasys).

CuraVAC is composed of medical grade polyurethane foam, adhesive drapes for sealing and connector tubings inside a sterile pouch.

Curasys is an improved portable vaccum device that offers distinct advantages over competing products due to its variable, continuous and cyclic vacuum options. It offers treatment flexibility, enhanced efficacy and results in less pain and discomfort for the patients.

Advantages of Negative Pressure Therapy

• increase in local functional blood perfusion
• accelerated rate of granulation tissue formation
• reduction in tissue bacteria level
• increase in nutrient blood flow

DAEWOONG PHARMA PHILIPPINES

C O M P A N  Y     P R O F I L E

Daewoong Pharma Phils Inc., the subsidiary of Daewoong Pharmaceutical Co., Ltd in Korea. Daewoong Pharmaceutical Co., Ltd. was established in 1945. It has the largest prescription drug sales in Korea and envisions itself to become a top 50 global healthcare company by 2012. Daewoong has maintained a steady growth rate in the double digits and has paid surplus dividends for the last 40 years.

In addition to its product portfolio, which includes 16 blockbuster products in Korea, Daewoong has built strong core competency for new drug development and has cultivated a cooperative culture for collaboration with global partners.

In the future, Daewoong will expand its global business with its foreign branches and global partners and become a global healthcare group which contributes to improving the quality of life for people worldwide.

Daewoong Pharma Phils Inc, was established in 2008. As of today we have 16 local distributors, 39 existing products with CPR and more products are still waiting for its registration. And some of our major products are wound  dressing kit for negative Pressure Wound Therapy, Curavac^TM and a bone grafting material  Bongros^®.

Recently, Daewoong Pharma Phils Inc sponsored students from College of Medicine and Pharmacy from the top universities (UP, ADMU and UST) to become Daewoong Scholars. We have several projects in line to be able to be a strong player in the Philippines market.